ClinicalTrials.gg
CompletedNCT02170701Updated Aug 31, 2018

BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery

A Phase 2 interventional study of BIBR 1048 in Venous Thromboembolism, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-31.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
289
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing dabigatran in Venous Thromboembolism — 1 open to participants now, 1 under way, none of them phase 3. Dabigatran · Venous Thromboembolism.

Enrollment
6th of 17
289 · median 148
Started
2000
the only one that year
Phase 2
7 of 17
none open now
Registered
11th of 17
by date
Lead sponsor
12 of 17
Boehringer Ingelheim

Among the 17 studies testing dabigatran in Venous Thromboembolism, this one is the 6th largest by enrollment, is the only one that started in 2000, is one of 7 in phase 2, and was the 11th registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

1 of the 17 studies testing dabigatran in Venous Thromboembolism is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About dabigatran

Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing dabigatran in Venous Thromboembolism, or all of them as a file.
02

Study summary

  • To determine the therapeutic window of BIBR 1048 in order to select doses for further studies in the development plan.
  • Twice daily regimen will be tested for most dose levels and once daily administration will also be evaluated when appropriate.
03

Conditions studied

  • Venous Thromboembolism
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled to undergo a primary elective total hip replacement
  • Male of female being 18 years or older
  • Patients weighing at least 40 kg
  • Written for study participation

Exclusion criteria

Exclusion Criteria:

  • Bleeding diathesis, constitutional or acquired coagulation disorders
  • Major surgery or trauma (e.g. hip fracture) within the last three months. Patients with previous hip fractures associated with plate revisions at any time will be excluded
  • Cardiovascular disease including uncontrolled hypertension at time of enrolment or history of myocardial infarction within the last 6 months
  • Any history of haemorrhagic stroke, intracranial or intraocular bleeding or cerebral ischaemic attacks
  • Known history of deep venous thrombosis (DVT)
  • Gastrointestinal or pulmonary bleeding within the last year
  • Known liver disease (AST) or Alanine transaminase (ALT) > 3 x )
  • Known renal disease (serum creatinine > 1.5 x ULN)
  • Use of long- term anticoagulants, antiplatelet drugs, or fibrinolytics within 7 days prior to hip replacement operation (also during the period of prophylaxis)
  • Women of
  • Known allergy to radiopaque contrast media
  • Known thrombocytopenia (prior count below 100,000 cells/microliter)
  • Active malignant disease
  • Current H2 blocker or proton pump inhibitor treatment
  • Current cytostatic treatment
  • Treatment with an drug in the past month
  • Leg amputee
  • Known alcohol or drug abuse
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
289 participants (actual)

Study arms

  • Experimental
    BIBR 1048

    Ascending doses (in mg) given twice daily

    Drug: BIBR 1048

Interventions

  • Ascending doses (in mg) given twice daily

06

What researchers measure

Primary outcomes

  1. Rate of venous thrombolic events

    Time frame: Up to day 10 after hip surgery

  2. Changes from baseline in activated partial thromboplastin time (aPTT)

    Time frame: From baseline (day -14 to day -1 before treatment) until last day of treatment (up to day 10)

  3. Changes from baseline in ecarin clotting time (ECT)

    Time frame: From baseline (day -14 to day -1 before treatment) until last day of treatment (up to day 10)

  4. Changes from baseline in thrombin time (TT)

    Time frame: From baseline (day -14 to day -1 before treatment) until last day of treatment (up to day 10)

  5. Rate of major bleeding events during treatment phase

    Time frame: Start of treatment (day 0) until end of treatment (up to day 10)

  6. Cpre,ss (predose plasma concentrations at steady state)

    Time frame: baseline and predose from day 1 to last treatment day

  7. Cmax,ss (maximum plasma concentration at steady state (day 4))

    Time frame: Day 4

  8. Tmax,ss (time to reach Cmax,ss)

    Time frame: baseline, day 0 before and 4 hours after, day 1 to 4 before and 2 h after treatment, day 5 to last treatment day before treatment

  9. CLtot/f (total clearance of drug from plasma after oral administration)

    Time frame: baseline, day 0 before and 4 hours after, day 1 to 4 before and 2 h after treatment, day 5 to last treatment day before treatment

  10. AUCss (area under the plasma concentration curve of one dosing interval at steady state)

    Time frame: baseline, day 0 before and 4 hours after, day 1 to 4 before and 2 h after treatment, day 5 to last treatment day before treatment

  11. PTF (percent peak trough fluctuation for the last dosing interval)

    Time frame: baseline, day 0 before and 4 hours after, day 1 to 4 before and 2 h after treatment, day 5 to last treatment day before treatment

  12. Cmax,ss (maximum plasma concentration at steady state (day 4))

    Time frame: Day 4 before and 0.5, 1, 2, 4 , 8, 12 , 14 h after treatment

Secondary outcomes

  1. Venous thromboembolism diagnosed during the follow-up period

    Time frame: Up to 6 weeks after surgery (day 42)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2000 and a primary completion of Jun 2001. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2014
First posted
Jun 23, 2014
Start
Oct 2000
Primary completionActual
Jun 2001
Last update
Aug 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02170701
Responsible party
Sponsor
First posted
Jun 23, 2014
Start date
Oct 2000
Primary completion
Jun 2001
Last update
Aug 31, 2018
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion